Precise by design
Each program is directed at a specific molecular regulator whose decline is tied to loss of function — precision at the root, not the symptom.
Science
Activome develops gene- and protein-restoration therapies with a single aim: to restore the biology that sustains human function, and that erodes with age.
Orientation
Across the conditions we pursue — sarcopenia, neurodegenerative disease, and age-related decline — one mechanism recurs: the body's capacity to repair and renew its own tissue weakens over time. That decline is not simple wear. It reflects the fading of specific molecular signals that coordinate regeneration — and because those signals are specific and molecular, they are targets, not inevitabilities.
Activome's science begins there. We work to identify the regulators of regeneration whose loss drives functional decline, and to develop therapies designed to restore them. Our orientation is mechanism-first: a clear rationale, disciplined preclinical work, and a deliberate path to the clinic.
The approach
Rather than manage the downstream symptoms of decline, Activome develops therapies designed to restore the upstream regulators of regeneration themselves.
Each program is directed at a specific molecular regulator whose decline is tied to loss of function — precision at the root, not the symptom.
Our therapies are designed to restore what age takes away, reactivating the body's own regenerative machinery.
We pursue durable, meaningful effect and long-term clinical relevance across related conditions.
Principles
In development. The work described here is in active, early-stage development. Activome's programs have not been approved by any regulatory authority, and we make no claim of safety or efficacy that has not been established.